Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study.
Xiaoye LiChengchun ZuoQiuyi JiYing XueZi WangQianzhou LvPublished in: Drug design, development and therapy (2021)
The fixed dose of 15 mg rivaroxaban might carry a risk of under exposure, which would lead to an increase of thromboembolic complications in patients with high BMI. Therefore, rivaroxaban dose increase was suggested for obese patients. Use of DOACs appears to have considerable safety in obese patients.
Keyphrases
- obese patients
- direct oral anticoagulants
- atrial fibrillation
- body mass index
- venous thromboembolism
- bariatric surgery
- gastric bypass
- roux en y gastric bypass
- oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- weight gain
- heart failure
- healthcare
- weight loss
- percutaneous coronary intervention
- risk factors
- physical activity
- left ventricular
- emergency department
- newly diagnosed
- acute care
- coronary artery disease